Division of Pathology,
Breakthrough Breast Cancer Research Unit
Dana Faratian has not added Biography.
If you are Dana Faratian and would like to personalize this page please email our Author Liaison for assistance.
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul, 2006 | Pubmed ID: 16754938
DCIS and aromatase inhibitors.
The Journal of steroid biochemistry and molecular biology Aug-Sep, 2007 | Pubmed ID: 17604618
Dynamic computational modeling in the search for better breast cancer drug therapy.
Pharmacogenomics Dec, 2007 | Pubmed ID: 18086005
Diesel exhaust inhalation increases thrombus formation in man.
European heart journal Dec, 2008 | Pubmed ID: 18952612
Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
Histopathology Jan, 2009 | Pubmed ID: 19207951
Pleural Wegener's granulomatosis: a rare presentation.
Histopathology Feb, 2009 | Pubmed ID: 19236522
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2009 | Pubmed ID: 19293255
Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.
Histopathology Mar, 2009 | Pubmed ID: 19309394
Systems pathology--taking molecular pathology into a new dimension.
Nature reviews. Clinical oncology Aug, 2009 | Pubmed ID: 19581910
Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.
Cancer research Aug, 2009 | Pubmed ID: 19638581
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.
Proceedings of the National Academy of Sciences of the United States of America Aug, 2009 | Pubmed ID: 19666588
Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Molecular cancer research : MCR Sep, 2009 | Pubmed ID: 19737968
How can systems pathology help us personalize cancer therapy?
Discovery medicine Aug, 2009 | Pubmed ID: 19788873
The importance of growth factors and steroid hormones in ovarian cancer.
Onkologie Nov, 2009 | Pubmed ID: 19887864
Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience.
Histopathology Nov, 2009 | Pubmed ID: 19912364
COX2 表达式在预后和预测内分泌治疗的早期乳腺癌患者。
Breast cancer research and treatment Feb, 2011 | Pubmed ID: 20358279
Pertuzumab for the treatment of ovarian cancer.
Expert opinion on biological therapy Jul, 2010 | Pubmed ID: 20465533
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
Breast cancer research : BCR , 2010 | Pubmed ID: 20569502
Cancer systems biology.
Methods in molecular biology (Clifton, N.J.) , 2010 | Pubmed ID: 20824475
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Cancer research Nov, 2010 | Pubmed ID: 20861192
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.
Cellular signalling Feb, 2011 | Pubmed ID: 20951800
Systems pathology.
Breast cancer research : BCR , 2010 | Pubmed ID: 21172088
Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.
European journal of cancer (Oxford, England : 1990) Jun, 2011 | Pubmed ID: 21334202
Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society Dec, 2010 | Pubmed ID: 21370594
What can molecular pathology contribute to the management of renal cell carcinoma?
Nature reviews. Urology May, 2011 | Pubmed ID: 21487387
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2011 | Pubmed ID: 21571868
Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer.
Clinical & experimental metastasis Dec, 2011 | Pubmed ID: 21789718
Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.
Breast cancer research and treatment Jul, 2011 | Pubmed ID: 21796367
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.
PloS one , 2011 | Pubmed ID: 21909357
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Cellular signalling Feb, 2012 | Pubmed ID: 21996585
GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.
BMC cancer , 2011 | Pubmed ID: 22051164
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences Nov, 2011 | Pubmed ID: 22085636
Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer.
Histopathology Jan, 2012 | Pubmed ID: 22168172
The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma.
PloS one , 2012 | Pubmed ID: 22363672
HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis.
Journal of clinical pathology Jul, 2012 | Pubmed ID: 22412045
Diversity of matriptase expression level and function in breast cancer.
PloS one , 2012 | Pubmed ID: 22514623
Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.
Cellular signalling Jan, 2013 | Pubmed ID: 23000339
Transcript and protein profiling identify signaling, growth arrest, apoptosis and NFκB-survival signatures following GnRH receptor activation.
Endocrine-related cancer Nov, 2012 | Pubmed ID: 23202794
Fiach C. O'Mahony1,
Jyoti Nanda1,
Alexander Laird1,
Peter Mullen2,
Helen Caldwell3,
Ian M. Overton4,
Lel Eory4,
Marie O'Donnell1,5,
Dana Faratian6,
Thomas Powles7,
David J. Harrison1,2,
Grant D. Stewart1
1Edinburgh Urological Cancer Group, University of Edinburgh,
2School of Medicine, University of St Andrews,
3Division of Pathology, University of Edinburgh,
4MRC Human Genetics Unit, MRC IGMM, University of Edinburgh,
5Department of Pathology, Western General Hospital,
6Breakthrough Breast Cancer Research Unit, University of Edinburgh,
7St Bartholomew's Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados